Abbvie Inc (ABBV) Volatility Spurs A Quest For Clarity

Currently, there are 1.77B common shares owned by the public and among those 1.76B shares have been available to trade.

The company’s stock has a 5-day price change of 1.21% and 16.60% over the past three months. ABBV shares are trading 16.60% year to date (YTD), with the 12-month market performance up to 14.42% higher. It has a 12-month low price of $130.96 and touched a high of $182.89 over the same period. ABBV has an average intraday trading volume of 5.66 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.73%, 3.27%, and 17.51% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Abbvie Inc (NYSE: ABBV) shares accounts for 71.95% of the company’s 1.77B shares outstanding.

It has a market capitalization of $319.18B and a beta (3y monthly) value of 0.57. The stock’s trailing 12-month PE ratio is 66.42, while the earnings-per-share (ttm) stands at $2.72. The company has a PEG of 17.91 and a Quick Ratio of 0.76 with the debt-to-equity ratio at 5.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.15% over the week and 1.46% over the month.

Analysts forecast that Abbvie Inc (ABBV) will achieve an EPS of $2.33 for the current quarter, $2.8 for the next quarter and $12.21 for 2025. The lowest estimate earnings-per-share for the quarter is $2.28 while analysts give the company a high EPS estimate of $2.4. Comparatively, EPS for the current quarter was $2.46 a year ago. Earnings per share for the fiscal year are expected to increase by 0.62%, and 9.38% over the next financial year. EPS should grow at an annualized rate of 3.71% over the next five years, compared to -5.77% over the past 5-year period.

Goldman was of a view on December 11, 2023 that the stock is Buy, while Deutsche Bank gave the stock Hold rating on November 09, 2023, issuing a price target of $150. Barclays on their part issued Overweight rating on October 30, 2023.

Most Popular

Related Posts